valdecoxib Bextra withdrawn
Selected indexed studies
- Celecoxib and cardiovascular risks. (Expert Opin Drug Saf, 2005) [PMID:16255660]
- Valdecoxib : the rise and fall of a COX-2 inhibitor. (Expert Opin Pharmacother, 2013) [PMID:23517091]
- Prostanoid receptor EP2 as a therapeutic target. (J Med Chem, 2014) [PMID:24279689]
_Worker-drafted node — pending editorial review._
Connections
valdecoxib Bextra withdrawn is a side effect of
Sources
- Valdecoxib : the rise and fall of a COX-2 inhibitor. (2013) pubmed
- Celecoxib and cardiovascular risks. (2005) pubmed
- Antitumor effects of valdecoxib on hypopharyngeal squamous carcinoma cells. (2022) pubmed
- Prostanoid receptor EP2 as a therapeutic target. (2014) pubmed
- Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. (2007) pubmed
- Cardiovascular effects of common analgesics. (2013) pubmed
- Cardiovascular issues of COX-2 inhibitors and NSAIDs. (2005) pubmed
- Progress in COX-2 inhibitors: a journey so far. (2010) pubmed
- cardioToxCSM: A Web Server for Predicting Cardiotoxicity of Small Molecules. (2022) pubmed
- Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? (2006) pubmed